Advertisement

Adjuvant Chemotherapy of Breast Cancer

Papers Presented at the 2nd International Conference on Adjuvant Chemotherapy of Breast Cancer, Kantonsspital St. Gallen, Switzerland, March 1 – 3, 1984

  • Hans-Jörg Senn

Part of the Recent Results in Cancer Research book series (RECENTCANCER, volume 96)

Table of contents

  1. Front Matter
    Pages I-XIII
  2. Scientific Basis of Adjuvant Chemotherapy in Breast Cancer

  3. Experience of Randomized Trials with Surgical Controls

    1. R. Nissen-Meyer, H. Høst, K. Kjellgren, B. Månsson, T. Norin
      Pages 48-54
    2. B. Fisher, E. R. Fisher, C. Redmond, Participating NSABP Investigators
      Pages 55-65
    3. G. Bonadonna, A. Rossi, G. Tancini, P. Valagussa, U. Veronesi
      Pages 66-73
    4. A. Howell, R. D. Rubens, H. Bush, W. D. George, J. M. T. Howat, D. Crowther et al.
      Pages 74-89
    5. H. J. Senn, W. F. Jungi, R. Amgwerd, E. Hochuli, J. Ammann, G. Engelhart et al.
      Pages 90-101
  4. Experience of Non-Randomized Trials with Historical or Mached Surgical Controls

    1. G. R. Blumenschein, A. U. Buzdar, G. N. Hortobagyi
      Pages 129-132
    2. S. E. Jones, R. J. Brooks, B. J. Takasugi, H. S. Garewal, G. F. Giordano, S. J. Ketchel et al.
      Pages 133-140
    3. A. U. Buzdar, T. L. Smith, C. E. Marcus, G. N. Hortobagyi, G. R. Blumenschein
      Pages 141-147
  5. Experience of Randomized Trials Without Surgical Controls

  6. Remaining Problems of Adjuvant Chemotherapy in Breast Cancer

  7. Closing Remarks and Outlook

    1. G. A. Nagel
      Pages 237-241
  8. Back Matter
    Pages 242-246

About this book

Introduction

H.-J. Senn Adjuvant Chemotherapy (ACT) of breast cancer has now emerged as one of the controversial su):>jects in clinical and also experimental oncology. Driven by growing frustration about stagnating cure rates in breast cancer [1,4] and stimulated by elegant demonstration of highly curative effects of adjuvant systemic therapy in animal models [6, 11] and in several childhood neoplasias [15], researchers introduced ACT to the primary treatment of breast cancer with great hope some 15 years ago. After a first wave of isolated "historic" trials with generally limited but in one case remarkable success [5, 9], a second generation of ACT studies was initiated by NSABP investigators and oncology centers in Europe [2, 6, 13]. These trials were well conducted statistically and diagnostically, and all in the early 1970s included a surgical control arm. Early and intermediate beneficial effects on relapse-free survival (RFS) after 2-3 years median observation time then prompted a whole series of ACT studies in breast cancer. These "third-gener­ ation" studies usually regarded some positive influence of ACT as a given fact, dropping surgical control regimens and comparing different ACT regimens, hopefully in a prospective, randomized way 1984 Fig. 1. The mushrooming of adjuvant studies in breast cancer XII Introduction [reviews in 3, 14]. The "mushrooming" of ACT studies in breast cancer during the last 10 and especially 5 years is demonstrated in Fig. 1, and it gets really cumbersome even for the insider to keep on top of the multitude of sometimes conflicting data.

Keywords

cancer chemotherapy child oncology research systemic therapy

Editors and affiliations

  • Hans-Jörg Senn
    • 1
  1. 1.Medizinische Klinik CKantonsspital St. GallenSt. GallenSwitzerland

Bibliographic information

  • DOI https://doi.org/10.1007/978-3-642-82357-2
  • Copyright Information Springer-Verlag Berlin Heidelberg 1984
  • Publisher Name Springer, Berlin, Heidelberg
  • eBook Packages Springer Book Archive
  • Print ISBN 978-3-642-82359-6
  • Online ISBN 978-3-642-82357-2
  • Series Print ISSN 0080-0015
  • Buy this book on publisher's site